A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT04157517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT04157517
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2019
- Primary completion
- Dec 19, 2023
- Completion
- Dec 19, 2023
- Last update posted
- Jan 28, 2026
2019 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center - Duarte | Duarte | California | 91010 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| The Angeles Clinic and Research Institute - West Los Angeles Office | Los Angeles | California | 90025 | — |
| University of Colorado Health Memorial Hospital Central | Colorado Springs | Colorado | 80909 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| Norris Cotton Cancer Center Lebanon | Lebanon | New Hampshire | 03756 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Cleveland Clinic Main Campus | Cleveland | Ohio | 44195 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Intermountain Medical Center | Murray | Utah | 84107 | — |
| West Virginia University Health Sciences Campus | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04157517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2026 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04157517 live on ClinicalTrials.gov.